Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19622773
Fan S, et al. (2009) Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res 69, 6083-91 19622773
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S1387-p - BRCA1 (human)
Modsite: EDCSGLSsQSDILTT SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1387‑p, BRCA1 iso6 (human): S284‑p, BRCA1 iso7 (human): S1387‑p, BRCA1 (mouse): S1343‑p, BRCA1 (rat): S1344‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioma, breast cancer
Relevant cell lines - cell types - tissues:  MDA-MB-231 (breast cell), T47D (breast cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ATM (human) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DIM increase

S1423-p - BRCA1 (human)
Modsite: AVLEQHGsQPSNSYP SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1423‑p, BRCA1 iso6 (human): S320‑p, BRCA1 iso7 (human): S1423‑p, BRCA1 (mouse): N1379‑p, BRCA1 (rat): S1380‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioma, breast cancer
Relevant cell lines - cell types - tissues:  MDA-MB-231 (breast cell), T47D (breast cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DIM no change compared to control

S1457-p - BRCA1 (human)
Modsite: SEKAVLTsQKsSEYP SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1457‑p, BRCA1 iso6 (human): S353‑p, BRCA1 iso7 (human): S1478‑p, BRCA1 (mouse): S1413‑p, BRCA1 (rat): S1414‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioma, breast cancer
Relevant cell lines - cell types - tissues:  MDA-MB-231 (breast cell), T47D (breast cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DIM no change compared to control

S1524-p - BRCA1 (human)
Modsite: LQNRNYPsQEELIKV SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1524‑p, BRCA1 iso6 (human): S420‑p, BRCA1 iso7 (human): S1545‑p, BRCA1 (mouse): S1481‑p, BRCA1 (rat): S1482‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioma, breast cancer
Relevant cell lines - cell types - tissues:  MDA-MB-231 (breast cell), T47D (breast cell), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DIM increase